Contract notice: Pharmaceutical products Tender, Germany - 14864538

Procurement Summary

Country : Germany

Summary : Contract notice: Pharmaceutical products

Deadline : 30 Jun 2018

Other Information

Notice Type : Tender

TOT Ref.No.: 14864538

Document Ref. No. : 273208-2017

Competition : ICB

Financier : Self Financed

Purchaser Ownership : -

Tender Value : Refer Document

Purchaser's Detail

Purchaser : KKH KAUFMÄNNISCHE KRANKENKASSE
Office Name: KKH Kaufmännische Krankenkasse
Address: Karl-Wiechert-Allee 61
Town: Hanover
Postal Code: 30625
Contact Point: zentrales Arzneimittelmanagement
Attention: Sven Seißelberg
Phone: +49 5112802-3376
Fax: +49 5112802-3396
Germany
Email :sven.seisselberg@kkh.de
URL :www.kkh.de

Tender Details

Object of the contract
Pharmaceutical products

Description: Contract notice: Pharmaceutical products

Authority Type: Body governed by public law
Contact Nature: Supplies
Procedure: Open procedure
Document: Contract notice
Regulation: European Union
Award criteria: Not specified
CPV code: 33600000, 33600000
CPV Description: Conclusion of non-exclusive discount agreements pursuant to - 130a para. 8 SGB V on latanoprost (ATC: S01EE01) only dosage form single-dipipettes with possible closure at any time under the so-called open-house procedure. Pursues the goal of discounting with all suitable pharmaceutical companiesPursuant to section 130a (8) SGB V on the basis of the above. In accordance with section 130a (8) of the Swiss Code of Obligations-SGB V to the o.g. Active substance. Interested pharmaceutical companies are able to do so under the following conditions: And the contract. At the same time as the requirement of the contract documents, the pharmaceutical company shall be required to submit appropriate authorizations for medicinal products with the above-mentioned. Active substance. The detection may e.g. uA corresponding extract of the AMIS database. The prerequisite for the conclusion of a contract is that the interested pharmaceutical company submits and submits the requested participation documents in full and signed. A contract is concluded with every pharmaceutical company that fulfills the prerequisites for participation. An exclusivity is not-given. The accession or conclusion of the contract may take place at any time and under the same conditions. Individual contract negotiations are not carried out.

The earliest start of the contract is 01.09.2017. If the KKH during the term of the contract for the active substances carries out an invitation to tender for exclusive contracts in the form of the open procedure, The present publication does not constitute the award of a public contract within the meaning of the Public Procurement Direc - tive of Directives. In order to ensure the greatest degree of transparency for the intended conclusion of the contract, the publication is made-In the Supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice shall be used. The resulting conceptual specifications, such as the procedure name "open procedure", are solely due to the use of this publication form and to the publishing platformThe following shall be subject to the provisions of this notice:

A contract shall be concluded not later than 10 days after the date of publication of this notice.

Information and formalities necessary for evaluating if requirements are met:

- Register of professional or commercial registers in duplicate (zum ZeitpuNty of the expiry of the time limit for the submission of tenders not more than 6 months), - Signed and stamped declaration of acceptance with respect to participation documents
Internet address (URL): www.kkh.de
Directive: Classical Directive (2004/18/EC)

Documents

 Tender Notice